UI retina surgeons collaborating on novel treatment study for AMD
Wednesday, April 09, 2014
Vitreoretinal disease specialists at the University of Iowa are working on a new treatment option for patients with “wet” age-related macular degeneration (AMD). The study, supported by biopharmaceutical company Oxford BioMedica, is evaluating the effect of RetinoStat, a lentiviral vector based treatment for neovascular wet AMD. The Phase 1 trial of RetinoStat involves 21 patients and tests a single subretinal administration of the drug. Currently available treatments for wet AMD involve frequent, repeated administration and can be costly.
“AMD is the number one cause of irreversible blindness in the elderly, and while recently discovered medicines can restore partial sight for some of those impacted by the 'wet' form of AMD, it requires monthly injections which in many patients can be indefinite. Decreasing the burden to patients from frequent injections is an active area of research. This trial, which is the first of its kind for macular degeneration, uses an innovative gene therapy approach as a potential one-time treatment for patients who lose vision from wet AMD. Completion of enrollment for this early human trial is a crucial step to making sure it is safe for use in larger numbers of patients,” states Dr. Elliott Sohn, who leads the UI team.
at Oxford Biomedica Web
at ClinicalTrials. gov